CAPOTEN Drug Patent Profile

When do Capoten patents expire, and when can generic versions of Capoten launch?

Capoten is a drug marketed by Strides Pharma and is included in one NDA.

The generic ingredient in CAPOTEN is captopril. There are fifteen drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the captopril profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Capoten

A generic version of CAPOTEN was approved as captopril by HIKMA INTL PHARMS on February 13^th, 1996.

Summary for CAPOTEN

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	118
Clinical Trials:	5
DailyMed Link:	CAPOTEN at DailyMed

Recent Clinical Trials for CAPOTEN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
GlaxoSmithKline	Phase 1
Children's Cancer Hospital Egypt 57357	Phase 3
University of Nebraska	Phase 4

See all CAPOTEN clinical trials

US Patents and Regulatory Information for CAPOTEN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Strides Pharma	CAPOTEN	captopril	TABLET;ORAL	018343-005	Jan 17, 1985		DISCN	Yes	No
Strides Pharma	CAPOTEN	captopril	TABLET;ORAL	018343-004	Jun 13, 1995		DISCN	Yes	No
Strides Pharma	CAPOTEN	captopril	TABLET;ORAL	018343-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No

Expired US Patents for CAPOTEN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Strides Pharma	CAPOTEN	captopril	TABLET;ORAL	018343-001	Approved Prior to Jan 1, 1982
Strides Pharma	CAPOTEN	captopril	TABLET;ORAL	018343-004	Jun 13, 1995
Strides Pharma	CAPOTEN	captopril	TABLET;ORAL	018343-005	Jan 17, 1985

International Patents for CAPOTEN

See the table below for patents covering CAPOTEN around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	222481	PROCEDIMIENTO PARA OBTENER DERIVADOS DE 1-(OMEGA-ALCANOILTIO O OMEGA-MERCAPTOALCONOIL)3,4-DESHIDROPROLINA
Denmark	507276
Yugoslavia	36379

CAPOTEN Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Capoten (Captopril)

Introduction to Capoten

Capoten, with the active ingredient captopril, is an angiotensin-converting enzyme (ACE) inhibitor widely used in the treatment of hypertension, congestive heart failure, and kidney problems caused by diabetes. It also improves survival after a heart attack.

Market Size and Growth

The ACE inhibitors market, which includes Capoten, has been experiencing steady growth. In 2023, the global ACE inhibitors market size was valued at $6.9 billion and is expected to grow to $7.24 billion in 2024, with a projected growth to $9 billion by 2028 at a compound annual growth rate (CAGR) of 5.6%[1].

Key Drivers of Market Growth

Several factors are driving the growth of the ACE inhibitors market, including:

Growing Global Burden of Cardiovascular Diseases

The increasing prevalence of cardiovascular diseases such as hypertension and heart failure is a significant driver. As the global population ages and the incidence of these diseases rises, the demand for effective treatments like ACE inhibitors increases[1][4].

Expanding Hypertension Treatment Guidelines

Updated treatment guidelines that recommend the use of ACE inhibitors for managing hypertension and heart failure contribute to market growth. These guidelines often emphasize the importance of early intervention and comprehensive treatment plans[1].

Advancements in Combination Therapies

The development of combination therapies that include ACE inhibitors is another key driver. These combinations often provide better outcomes and are preferred by healthcare providers for managing complex conditions[1].

Focus on Heart Failure Management

The increasing focus on heart failure management, particularly in terms of reducing morbidity and mortality, drives the demand for ACE inhibitors like Capoten[1].

Market Segmentation

The ACE inhibitors market is segmented by type, drug, and dosage form.

By Type

• Sulfhydryl-containing Agents
• Dicarboxylate-containing Agents
• Phosphonate-containing Agents Capoten falls under the sulfhydryl-containing agents category, which is expected to be a fast-growing segment[1].

By Drug

• Ramipril
• Enalapril
• Benazepril
• Fosinopril
• Captopril (Capoten)
• Moexipril
• Other drugs Capoten is one of the prominent drugs in this segment[1].

By Dosage Form

• Oral Tablets
• Oral Solutions Capoten is available in various dosage strengths (12.5 mg, 25 mg, 50 mg, and 100 mg) in oral tablet form[1].

Regional Market Dynamics

North America

North America was the largest region in the ACE inhibitors market in 2023. The North America ACE Inhibitors Market was valued at USD 2.18 Billion in 2023 and is anticipated to grow with a CAGR of 5.25% through 2029[4].

Asia-Pacific

The Asia-Pacific region is expected to be the fastest-growing region during the forecast period. This growth is driven by increasing healthcare access, rising awareness of cardiovascular diseases, and improvements in healthcare infrastructure[1].

Competitive Landscape

The market for ACE inhibitors, including Capoten, is highly competitive with several key players.

Major Companies

• Pfizer
• Novartis
• AstraZeneca
• Camber Pharmaceuticals Inc.

In November 2021, Camber Pharmaceuticals Inc. launched a generic version of Capoten, which has helped in increasing market competition and accessibility[1].

Recent Developments

AstraZeneca's acquisition of CinCor Pharma in January 2023 for $1.3 billion is expected to expand its product line and enhance its position in the market. This acquisition focuses on developing novel treatments for resistant and uncontrolled hypertension as well as chronic kidney disease[1].

Financial Trajectory

The financial performance of companies involved in the ACE inhibitors market is influenced by several factors, including market growth, competition, and regulatory environments.

Revenue Growth

The revenue from ACE inhibitors is expected to grow significantly, driven by the increasing demand for these drugs. For instance, the global ACE inhibitors market is projected to reach $9 billion by 2028[1].

Generic Competition and Pricing Pressures

The launch of generic versions of drugs like Capoten by companies such as Camber Pharmaceuticals Inc. introduces pricing pressures. However, this also makes the drug more accessible to a wider population, contributing to overall market growth[1].

Regulatory Updates and Safety Considerations

Regulatory updates and safety considerations play a crucial role in the market dynamics of ACE inhibitors. Companies must adhere to stringent regulatory standards to ensure the safety and efficacy of their products. Any changes in regulations or safety guidelines can impact the market significantly[1].

Patient-Centric Approaches

The healthcare industry is increasingly adopting patient-centric approaches, which include personalized treatment plans and better patient outcomes. ACE inhibitors like Capoten are part of these approaches, enhancing patient care and satisfaction[1].

Key Takeaways

• The ACE inhibitors market, including Capoten, is expected to grow significantly due to the increasing global burden of cardiovascular diseases.
• The market is driven by expanding treatment guidelines, advancements in combination therapies, and a focus on heart failure management.
• North America is the largest market, while the Asia-Pacific region is expected to be the fastest-growing.
• The competitive landscape is characterized by key players like Pfizer, Novartis, and AstraZeneca.
• Generic competition and regulatory updates are significant factors influencing the market.

FAQs

Q: What is Capoten used for? A: Capoten, with the active ingredient captopril, is used to treat hypertension, congestive heart failure, kidney problems caused by diabetes, and to improve survival after a heart attack[1].

Q: What is the expected growth rate of the ACE inhibitors market? A: The ACE inhibitors market is expected to grow at a CAGR of 5.6% from 2023 to 2028[1].

Q: Which region is the largest market for ACE inhibitors? A: North America is the largest region in the ACE inhibitors market[1].

Q: Who are the key players in the ACE inhibitors market? A: Key players include Pfizer, Novartis, AstraZeneca, and Camber Pharmaceuticals Inc.[1].

Q: What are the main drivers of the ACE inhibitors market? A: The main drivers include the growing global burden of cardiovascular diseases, expanding hypertension treatment guidelines, advancements in combination therapies, and a focus on heart failure management[1].

Cited Sources

1. The Business Research Company, "Global ACE Inhibitors Market Report 2024".
2. Capital Bancorp, Inc., "CBNK Announces Record Quarterly Earnings".
3. Market Research Intellect, "Global Prilide Antihypertensive Drugs Market Size, Trends and ...".
4. TechSci Research, "North America ACE Inhibitors Market By Size, Share and Forecast ...".